All Over For Servier's Autism Ambitions
Neurochlore-Partnered Bumetanide Fails in Phase III
The diuretic bumetanide had shown potential to improve the core symptoms of children and adolescents with autism in small studies but has failed to demonstrate any sign of effectiveness in two late-stage trials.
You may also be interested in...
Following last year's licensing deal with Precision Biosciences and the acquisition of Prevail Therapeutics, Eli Lilly is expanding its gene therapy efforts by backing Jaguar, a start-up staffed by former AveXis bosses.
Novartis is the latest big pharma to sign up for access to Sangamo's gene therapy technologies, inking a deal that will focus on neurodevelopment disorders and could be worth in the region of $800m.
The Phase III PROpel study has shown that a combination of AstraZeneca's Lynparza and Johnson & Johnson's Zytiga significantly delayed disease progression as a first-line treatment for men with metastatic castration-resistant prostate cancer.